Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deuterated caffeine is a **small molecule** deuterated isotopologue of caffeine in which the nine hydrogen atoms of the 1, 3, and 7 methyl groups are replaced with deuterium. It is being developed by **d9 Designs** for food, beverage, cosmetic, and potential clinical uses. Pharmacologically, it is intended to retain caffeine's core activity as an **adenosine receptor antagonist** while altering CYP1A2-mediated metabolism through deuterium substitution, with reported longer-lasting stimulant effects, potentially lower dose requirements, and reduced exposure to downstream caffeine metabolites. Publicly described potential medical applications include **apnea in premature infants** and use as an **analgesic adjuvant in pain management**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deuterated caffeine.